Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Bullous Diseases
NCT07011589Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jan 2028
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in Recessive Dystrophic Epidermolysis Bullosa (RDEB), dystrophic epidermolysis bullosa (DEB), epidermolysis bullosa acquisita (EBA). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)dystrophic epidermolysis bullosa (DEB)epidermolysis bullosa acquisita (EBA)
Beyond the preview
Go deeper on NCT07011589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07011589.